BBH - VanEck Vectors Biotech ETF
| Assets | $518.86M |
| NAV | $183.90 |
| Expense Ratio | 0.35% |
| PE Ratio | 26.71 |
| Beta (5Y) | 0.90 |
| Dividend (ttm) | $0.61 |
| Dividend Yield | 0.33% |
| Ex-Dividend Date | Dec 21, 2020 |
| 1-Year Return | - |
| Trading Day | April 20 |
| Last Price | $183.44 |
| Previous Close | $183.65 |
| Change ($) | -0.21 |
| Change (%) | -0.11% |
| Day's Open | 182.58 |
| Day's Range | 181.31 - 185.00 |
| Day's Volume | 12,151 |
| 52-Week Range | 144.21 - 197.28 |
Fund Description
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
| Asset Class Equity | Sector Biotech |
| Region North America | Inception Date Dec 20, 2011 |
| Exchange NASDAQ | Ticker Symbol BBH |
| Index Tracked MVIS US Listed Biotech 25 Index | |
Top 10 Holdings
54.84% of assets| Name | Symbol | Weight |
|---|---|---|
| Amgen | AMGN | 9.89% |
| Moderna | MRNA | 5.76% |
| IQVIA Holdings | IQV | 5.25% |
| Gilead Sciences | GILD | 5.08% |
| Alexion Pharmaceuticals | ALXN | 4.96% |
| Regeneron Pharmaceuticals | REGN | 4.92% |
| Novavax Inc | n/a | 4.89% |
| Biogen | BIIB | 4.72% |
| Vertex Pharmaceuticals | VRTX | 4.71% |
| Illumina | ILMN | 4.66% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 21, 2020 | $0.6079 | Dec 28, 2020 |
| Dec 23, 2019 | $0.416 | Dec 30, 2019 |
| Dec 20, 2018 | $0.551 | Dec 27, 2018 |
| Dec 18, 2017 | $0.683 | Dec 22, 2017 |
| Dec 19, 2016 | $0.26 | Dec 23, 2016 |
| Dec 21, 2015 | $0.34 | Dec 28, 2015 |
Some biotech and pharmaceutical ETFs are gaining on Tuesday despite news that Johnson and Johnson's coronavirus vaccine has been halted in over two dozen states, after the Food and Drug Administration r...
The United States and China have been locking horns when it comes to technological advances. ETF investors looking to capitalize on strength in U.S. biotech should give the VanEck Vectors® Biotech ETF (...
Investors looking to reduce the risk of owning some of 2021's best stocks might consider these 10 ETFs to buy instead. The post 10 ETFs to Buy to Mimic 2021's Best Stock Picks appeared first on Investor...
Biotechnology sector-related exchange traded funds strengthened after Illumina (NasdaqGS: ILMN) announced better-than-expected quarterly earnings and an optimistic 2021 outlook. On Friday, the VanEck Ve...
2020 saw a lot of initial public offerings (IPOs) put on hold thanks to Covid-19. Now that a global vaccine rollout is underway, biotech IPOs are hitting the markets and boosting the VanEck Vectors® Bio...
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.
By Michael Cohick, Senior ETF Product Manager, VanEck Recent positive developments in COVID-19 vaccines have spurred a wave of market exuberance, lifting share prices of biotech companies at the forefro...
AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion ...
November has been a big month for stock and biotech ETFs, and with the Federal Aviation Administration announcing that it supported the “first mass air shipment” of coronavirus vaccines on Friday, pharm...
Healthcare stocks and ETFs are continuing to outperform as investors are optimistic about an upcoming vaccine for the coronavirus, which has been a blight on the globe since early this year. There has b...
The COVID-19 pandemic has given way to new technological innovations in the biotechnology sector with respect to creating a vaccine. ETF investors looking for a play that can take them well into 2021 mi...
Monday saw stocks and index ETFs surge, after the announcement from Pfizer that the pharmaceutical giant had a vaccine candidate with an over 90% effectiveness in clinical trials. Now another biotech, M...
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.
As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds, ...
With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.
The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.
The race to introduce vaccine and treatment of coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
Biotech Sector Chart The broad stock market’s two day rally saw biotech stocks surge higher. In particular, the reversal in Biotech Sector ETFs BBH and XBI looks to be bullish.
Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.
Nine vaccine developers have jointly pledged to observe high ethical standards in conducting clinical studies and manufacturing of vaccines.
AstraZeneca's initiation of a phase III study has heated up competition to bring a coronavirus vaccine to the markets.
For the first four months of the market’s cornavirus recovery, one of the key themes was the dominance of biotech.
Stock indexes and ETFs rocketed higher and are continuing the uptrend in trading Wednesday after Moderna said its coronavirus vaccine generated antibodies in elderly patients for the first time, creatin...
Coronavirus treatment: FDA authorizes convalescent plasma for COVID-19 use
Yahoo Finance's Anjalee Khemlani reports on the FDA's approval on the use of convalescent plasma to treat COVID-19.
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q2 earnings releases amid the coronavirus crisis.
Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.
The race to find a coronavirus vaccine is heating up as the latest positive data from progress in trials are being published.
Stock futures rocketed higher and are continuing the uptrend in overnight trading on Tuesday after Moderna said its coronavirus vaccine generated antibodies in all patients in an early trial, creating o...
As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.
With a slew of news to start off the month and quarter, biotech equities and ETFs are moving higher on Wednesday with optimism over developments on the coronavirus vaccine front. The Dow Jones Industria...
In a sea of red stocks on Wednesday, as fear grips markets due to another spike in coronavirus cases throughout the country, Gilead Sciences is one of the few bright spots in the stock market.
In the continuing quest to find a vaccine for the coronavirus, the World Health Organization announced Wednesday it is dropping hydroxychloroquine, the malaria drug backed by President Trump, who claims...
In the race to develop a coronavirus vaccine, AstraZeneca (NYSE: AZN) and Gilead Sciences (NASDAQ: GILD) are two of the leading contenders and that could be the starting point of a massive marriage, acc...
Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.
From VanEck Global With the COVID-19 pandemic showing few signs of easing, biotech companies are racing to meet soaring demand for treatments, vaccines and testing kits. This is helping to drive renewed...
Novavax's latest progress in the Covid-19 vaccine development brings optimism to the Wall Street.
There’s no denying biotechnology ETFs are benefiting from the race to cure and treat and the novel coronavirus. Just look at the VanEck Vectors Biotech ETF (BBH), which is higher by more than 7% over ju...
With the race to find a vaccine for the coronavirus, now drugmaker AstraZeneca is the latest to receive funding to generate a panacea.
Positive data on early-stage coronavirus vaccine trial sent Moderna shares surging.
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q1 earnings releases amid the coronavirus crisis.
Rising investor interest in coronavirus related stocks will benefit these ETFs
As the coronavirus continues to spread, the latest positive data on remdesivir is some relief in such challenging times.
The healthcare space is heated up with players rushing to come up with a vaccine for COVID-19.
